Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urothelial Carcinoma Bladder: early-phase trial registry
8 of 17 indexed Urothelial Carcinoma Bladder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 8 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Urothelial Carcinoma Bladder: 17 US clinical trials tracked, 8 recruiting.
Urothelial Carcinoma Bladder is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, running 3 of these trials.
Enrollment posture brief
Registry condition urothelial-carcinoma-bladder
OPEN 8 | RECR 47% | LATE 3 | EARLY 12 | RANK #1004 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Bone Loss (47% recruiting · 17 trials)
Urothelial Carcinoma Bladder lists 8 open slots (47% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urothelial Carcinoma Bladder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urothelial Carcinoma Bladder recruits in line with its size-band peers.
8 of 17 indexed trials (47.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Urothelial Carcinoma Bladder research.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins accounts for 3 of 17 trials (17.6%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Urothelial Carcinoma Bladder trials plan to enrol fewer than 100 people.
Median target enrolment is 63 among the 17 trials that report a genuine target (sentinel values excluded). 13 of those (76.5%) plan for fewer than 100 participants.
-
Urothelial Carcinoma Bladder research is mostly interventional.
15 interventional and 2 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Elephas
NCT05520099
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology
NCT07020117
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
University of Florida
NCT06184516
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05312671
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
NCT05483868
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Brown University
NCT05839119
Renal Retention in High Grade Upper Tract Urothelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05656235
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Abramson Cancer Center at Penn Medicine
NCT06586255
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma
NCT05243550
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
UroGen Pharma
NCT06331299
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
Pangea Laboratory
NCT06870253
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
IO Biotech
NCT05077709
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
The Methodist Hospital Research Institute
NCT05241340
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04386746
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
NCT03236935
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT04200963
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma
NCT05136898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 6 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Urothelial Carcinoma Bladder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urothelial Carcinoma Bladder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urothelial Carcinoma Bladder page
17 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Urothelial Carcinoma Bladder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most Urothelial Carcinoma Bladder trials on record, review their full trial history before evaluating a specific study. See Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urothelial Carcinoma Bladder condition card totals 17 registered trials; most-linked intervention UGN-102; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.